Clinical Trial: Newborn Screening for Adrenoleukodystrophy
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: Newborn Screening for Adrenoleukodystrophy
Brief Summary: To test if the routine newborn screening dried blood spots can be used to test if elevation of C26:0 lysophosphatidylcholine (C26:0-lyso-PC), a status indicating adrenoleukodystrophy (ALD)
Detailed Summary: Parents of newborns will be invited to test if their newborns are affected with ALD. The routine newborn screening dried blood spots sample will be used to test the concentration of C26:0-lyso-PC . If positive of a screening test, further confirmation tests including physical examination and other methodology for ALD confirmation will be provided. Genetic counseling and treatment option will be provided, too.
Sponsor: National Taiwan University Hospital
Current Primary Outcome: numbers of newborn with ALD [ Time Frame: 12 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: National Taiwan University Hospital
Dates:
Date Received: October 31, 2016
Date Started: November 2016
Date Completion: June 2018
Last Updated: January 5, 2017
Last Verified: January 2017